Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Research Works Act: One (Two!) Against and One For | Main | Dapagliflozin Goes Down (For the Last Time?) »

January 19, 2012

Takeda Announces Cuts

Email This Entry

Posted by Derek

2,800 over the next four years. More of them are in Europe than in the US (via the Nycomed acquisition), but there are hundreds of positions to be lost in this country, too. For now, the company seems to be just saying that they'll be in all parts of the organization, without much in the way of details. Those will, in time, become all too apparent.

Add that to last week's Novartis announcement (about 2,000 jobs, mostly in sales and marketing), and we're not off to a great 2012 on this front, are we?

Comments (15) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. You're Pfizered on January 19, 2012 9:17 AM writes...

And the hits keep right on coming...

Bets on who is next to purge?

Permalink to Comment

2. Chemjobber on January 19, 2012 9:39 AM writes...

I do not enjoy waiting for shoes to drop, but I fear there are more to come.

Permalink to Comment

3. Just sayin' on January 19, 2012 9:59 AM writes...

And here I am reading C&EN's coverage of the recent JP Morgan Healthcare Conference in San Francisco. Gotta love the quotes from the movers and shakers:

"The tenor is definitely better this year."

"...rational optimism..."

"Good money available for good products."

"We are very bullish right now on the environment for early-stage life sciences."

Permalink to Comment

4. Anonymous on January 19, 2012 10:03 AM writes...

At least one thing is for sure right now according to the news: Takeda is closing the whole R&D facility with round about 700 employees in Konstanz/Germany. This is the former Byk-Gulden and Altana site where draugs like pantoprazole or roflumilast (trade name Daxas) were discovered.

Permalink to Comment

5. anonymous on January 19, 2012 10:07 AM writes...

At least one thing is for sure right now according to the news: Takeda is closing the whole R&D facility with round about 700 employees in Konstanz/Germany. This is the former Byk-Gulden and Altana site where draugs like pantoprazole or roflumilast (trade name Daxas) were discovered.

Permalink to Comment

6. PharmaHeretic on January 19, 2012 11:25 AM writes...

Any guesses on the end game of pharma? The upper management can't pay themselves that much if they go all generic, because of lower profits.

Permalink to Comment

7. Anonymous on January 19, 2012 1:22 PM writes...

Why did they buy the company in the first place? They obviously wanted something, and it wasn't the staff. Happens time and time again. How is this a sensible way to run a global economy?

Permalink to Comment

8. @PharmaHeretic on January 19, 2012 3:58 PM writes...

Courtesy of Luke Timmerman at Xconomy, here is a frightening look into Chris Viehbacher's (CEO of Sanofi-Aventis) pharma strategery:

Q: On Sanofi’s outreach strategy with U.S. researchers, particularly in the Boston area following the Genzyme acquisition:

A: One of the main rationales for doing the Genzyme deal was to have a strong presence in research in the U.S., and clearly the first choice is Cambridge. Our vision for research is one of open collaboration. How companies do research is evolving, and certainly we are evolving. Traditionally, we’ve had big research centers, and we are trying to get a lot more balance between internal research and external research. Right now, it’s about a 70/30 ratio between internal to external. My objective is to bring that to about a 50/50 balance.


Permalink to Comment

9. CR on January 19, 2012 4:29 PM writes...

Viehbacher wants "open collaboration"...wasn't that what Abby PharmTech was providing?

Permalink to Comment

10. anonymous on January 19, 2012 8:34 PM writes...

@1. You're Pfizered:
Believe me when I tell you (relative to your question) that you place a high wager on Merck (and the song plays on....)!

Permalink to Comment

11. anonymous on January 19, 2012 8:34 PM writes...

@1. You're Pfizered:
Believe me when I tell you (relative to your question) that you can place a high wager on Merck (and the song plays on....)!

Permalink to Comment

12. Ginsberg on January 20, 2012 8:05 AM writes...

Alnylam is laying off 33% of their staff now. That amounts to about 56 jobs. Small potatoes compared to Tekeda but still a lot of money and man hours have been wasted on the RNAi snake oil.

Permalink to Comment

13. LegaceMerckguy on January 20, 2012 6:37 PM writes...

@ 11 and 1: I bet it's Merck also. Every year for the last 10 we have had some sort of layoff. I can tell you one thing, I am waiting for our Abby Pharmtech. It really is only a matter of time.

Permalink to Comment

14. PorkPieHat on January 21, 2012 7:55 PM writes...

While what Alnylam was doing was really fascinating, it never struck me as being commercially viable.

Permalink to Comment

15. Chrispy on July 30, 2012 6:28 AM writes...

Novo Nordisk just shed 40 odd in the UK and several hundred in Europe. Anything to do with Greece not being able to pay for it's Insulin?????

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Molecular Printing of Drug Molecules. Say What?
Pfizer Walks Again By Night
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi